Teva Responds To API Unit Selloff Rumors

Company Says TAPI Remains ‘A Strong Business’ But Acknowledges Reports Of Sale

Amid rumors that Teva is mulling a potential sale of its APIs business, TAPI, the Israeli firm has underlined the strength of the unit while acknowledging that it continuously reviews such opportunities.

Deal - Yes or No? Spelled out on cubes
Rumors are swirling that Teva is mulling a deal for TAPI • Source: Shutterstock

Amid rumors of a potential sale by Teva of its Teva Active Pharmaceutical Ingredients unit, the generics giant has underlined the strength of the TAPI business and its increasingly standalone nature while acknowledging that it continuously reviews business opportunities.

A recent report in Bloomberg claimed that the generics giant was “weighing options for its active ingredients business, including a...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business